| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Raffin Thomas A. | Director | C/O AKOYA BIOSCIENCES, INC., 100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH | /s/ Thomas A. Raffin | 10 Jul 2025 | 0001512119 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | AKYA | Common Stock | Other | -234,592 | -100% | 0 | 08 Jul 2025 | Thomas A. Raffin Living Trust dated March 29, 2017 | F1, F2 | ||
| transaction | AKYA | Common Stock | Other | -1,737,712 | -100% | 0 | 08 Jul 2025 | See footnote 3 | F1, F2, F3 | ||
| transaction | AKYA | Common Stock | Other | -15,937,535 | -100% | 0 | 08 Jul 2025 | See footnote 4 | F1, F2, F4 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | AKYA | Stock Option (Right to Buy) | Other | $0 | -16,860 | -100% | $0.000000 | 0 | 08 Jul 2025 | Common Stock | 16,860 | $21.95 | Direct | F5, F6 |
| transaction | AKYA | Stock Option (right to buy) | Other | $0 | -30,549 | -100% | $0.000000 | 0 | 08 Jul 2025 | Common Stock | 30,549 | $11.24 | Direct | F5, F6 |
| transaction | AKYA | Stock Option (right to buy) | Other | $0 | -56,322 | -100% | $0.000000 | 0 | 08 Jul 2025 | Common Stock | 56,322 | $5.70 | Direct | F5, F6 |
| transaction | AKYA | Stock Option (right to buy) | Other | $0 | -50,000 | -100% | $0.000000 | 0 | 08 Jul 2025 | Common Stock | 50,000 | $2.01 | Direct | F5, F6 |
Thomas A. Raffin is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.
| Id | Content |
|---|---|
| F1 | Disposition of shares pursuant to that certain Amended and Restated Agreement and Plan of Merger dated as of April 28, 2025, as amended (the "Merger Agreement"), by and among Quanterix Corporation, a Delaware corporation ("Quanterix"), Wellfleet Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Quanterix ("Merger Sub"), and Issuer. On July 8, 2025 (the "Closing Date"), Merger Sub merged with and into Issuer (the "Merger"), with Issuer surviving the Merger as a wholly owned subsidiary of Quanterix. |
| F2 | In connection with the terms of the Merger Agreement, each share of common stock of Issuer outstanding on the Closing Date was converted into the right to receive (a) 0.1461 of a share of common stock of Quanterix (the "Per Share Stock Consideration") and (b) $0.38 in cash, without interest (the "Per Share Cash Consideration" and together with the Per Share Stock Consideration, the "Per Share Merger Consideration"). Each of the Per Share Stock Consideration and the Per Share Cash Consideration may be adjusted pursuant to the terms of the Merger Agreement. |
| F3 | Shares held directly by THP III Affiliates Fund, LLC ("THP III AFF"). Telegraph Hill Partners III Investment Management, LLC ("THP IM") is the manager of THP III AFF. Telegraph Hill Partners Management Company, LLC ("THPMC") is the manager of THP IM. J. Matthew Mackowski, Dr. Thomas A. Raffin and Deval Lashkari are each managers of THPMC and may be deemed to share voting and dispositive power over the securities held by THP III AFF. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. |
| F4 | Shares held directly by Telegraph Hill Partners III, L.P. ("THP III"). THP IM is the general partner of THP III. THPMC is the manager of THP IM. J. Matthew Mackowski, Dr. Thomas A. Raffin and Deval Lashkari are each managers of THPMC and may be deemed to share voting and dispositive power over the securities held by THP III. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. |
| F5 | Disposition of options pursuant to Merger Agreement. |
| F6 | Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration. |